公开(公告)号：US12090230B2

公开(公告)日：2024-09-17

申请号：US17979346

申请日：2022-11-02

Applicant: Fermented Farmer, LLC

Inventor： Jordan Seth Rubin

IPC: A61K36/00 ,  A23L33/105 ,  A23L33/135 ,  A23L33/21 ,  A23P10/30 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48 ,  A61K36/185 ,  C12N1/20 ,  A61K31/352

CPC classification number: A61K9/20 ,  A23L33/105 ,  A23L33/135 ,  A23L33/21 ,  A23P10/30 ,  A61K9/0053 ,  A61K9/48 ,  A61K36/185 ,  C12N1/20 ,  A61K31/352

Abstract: The present invention is a cannabidiol oral dosage form including predominantly or exclusively bacterially fermented hemp pomace, compounded as a tablet or formulated within a capsule generally without the addition of synthetic excipients, fillers or other additives, not including the inevitable presence of some moisture. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of one part soluble dietary fiber to 30 parts insoluble dietary fiber and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG, etc.) in a ratio of 60:1 up to 120:1 to hallucinogenic cannabinoids (THC).

公开(公告)号：US12090186B2

公开(公告)日：2024-09-17

申请号：US17222768

申请日：2021-04-05

Applicant: Moringo Organics Inc.

Inventor： Karen Vieira ,  John Britto

IPC: A61K36/00 ,  A61K9/00 ,  A61K9/48 ,  A61K31/4525 ,  A61K35/04 ,  A61K35/74 ,  A61K35/748 ,  A61K36/185 ,  A61K36/31 ,  A61K36/47 ,  A61K36/48 ,  A61K36/53 ,  A61K36/61 ,  A61K36/67 ,  A61K36/9066 ,  A61P3/06 ,  A61P3/10 ,  A61P39/06

CPC classification number: A61K36/31 ,  A61K9/0053 ,  A61K9/48 ,  A61K31/4525 ,  A61K35/04 ,  A61K35/74 ,  A61K35/748 ,  A61K36/185 ,  A61K36/47 ,  A61K36/48 ,  A61K36/53 ,  A61K36/61 ,  A61K36/67 ,  A61K36/9066 ,  A61P3/06 ,  A61P3/10 ,  A61P39/06 ,  A61K2300/00 ,  A61K2300/00 ,  A61K36/185 ,  A61K2300/00 ,  A61K36/47 ,  A61K2300/00 ,  A61K36/48 ,  A61K2300/00 ,  A61K36/53 ,  A61K2300/00 ,  A61K36/67 ,  A61K2300/00 ,  A61K36/9066 ,  A61K2300/00 ,  A61K35/74

Abstract: The main objective of the present invention is to develop an herbal formulation with high polyphenol concentrations. A therapeutic effect of ingredients in herbal composition with Antioxidants, Anti-inflammatories, Anti Viral & Anti Microbial properties to reduce Oxidative Stress, Inflammation, Viral and Microbial Infections. The herbal composition promotes management of diabetes, regulation of cholesterol, also immune system processes that helps to fight against viral and bacterial infections, colds, or the flu, skin ailments such as Psoriasis & eczema. Herbal Composition comprises synergistic combination of Moringa oleifera Leaf Powder, Spirulina & Aqueous extracts of Oregano vulgare Leaf Extract, Shilajit extract, Rosemary Leaf extract, Pomegranate Fruit Preel extract, Amla fruit extract, Fenugreek Seed Extract, Curcumin Extract, Piperine extract. Therefore, the chosen herbal blend provides the body with all of the vitamins, minerals, and nutrients it needs to continuously boost health.

公开(公告)号：US20240301022A1

公开(公告)日：2024-09-12

申请号：US18598878

申请日：2024-03-07

Applicant: Aston University

Inventor： Michael J. Tisdale ,  Steven T. Russell

IPC: C07K14/47 ,  A23L33/17 ,  A61K9/00 ,  A61K31/137 ,  A61K31/138 ,  A61K38/17 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  A61K47/60 ,  A61K47/61

CPC classification number: C07K14/473 ,  A23L33/17 ,  A61K9/0014 ,  A61K9/0043 ,  A61K9/0053 ,  A61K31/137 ,  A61K31/138 ,  A61K38/17 ,  A61K38/1709 ,  A61K38/1741 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  A61K47/60 ,  A61K47/61

Abstract: The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents.

公开(公告)号：US20240299482A1

公开(公告)日：2024-09-12

申请号：US18430296

申请日：2024-02-01

Applicant: Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Lakshmi Mundkur ,  Mohammad Mansoor Ansari

Inventor： Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Lakshmi Mundkur ,  Mohammad Mansoor Ansari

IPC: A61K36/8905 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48 ,  A61K31/05 ,  A61K31/343 ,  A61K36/185

CPC classification number: A61K36/8905 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/4866 ,  A61K31/05 ,  A61K31/343 ,  A61K36/185 ,  A61K2236/15 ,  A61K2236/33 ,  A61K2236/37 ,  A61K2236/39 ,  A61K2236/51 ,  A61K2236/55

Abstract: The invention discloses a composition comprising Cyperus rotundus extract and Passiflora edulis extract comprising piceatannol, scirpusin B, scirpusin A, cyperusphenol A and cyperusphenol B, standardized to contain 6-10% w/w total stilbenes and a process of preparing the composition thereof. The invention also discloses the use of the above mentioned composition in enhancing energy expenditure in mammalian adipose cellular systems by the conversion of white adipose tissues to brown adipose tissues, inhibition of adipogenesis and for preventing weight gain in mammals.

公开(公告)号：US20240299384A1

公开(公告)日：2024-09-12

申请号：US18547959

申请日：2022-02-25

Applicant: ACTELION PHARMACEUTICALS LTD

Inventor： Mark ROCCO ,  Mona SELEJ ,  Carol ZHAO

IPC: A61K31/506 ,  A61K9/00 ,  A61K9/28 ,  A61M60/90 ,  A61P9/12

CPC classification number: A61K31/506 ,  A61K9/0053 ,  A61K9/28 ,  A61M60/90 ,  A61P9/12

Abstract: The present disclosure provides methods for treating pulmonary hypertension in a patient with left ventricular assist device (LVAD) implantation and methods of improving cardiac transplant eligibility in a patient with LVAD implantation. The methods include administering to a patient in need thereof a therapeutically effective amount of macitentan or aprocitentan.

公开(公告)号：US20240299381A1

公开(公告)日：2024-09-12

申请号：US18488456

申请日：2023-10-17

Applicant: AbbVie Inc.

Inventor： Sandra L. Goss ,  Cheri E. Klein ,  Juki Wing-Keung Ng ,  Ahmed Salem

IPC: A61K31/505 ,  A61K9/00 ,  A61K31/4178 ,  A61K31/496 ,  A61K31/513 ,  A61K31/565 ,  A61K31/567

CPC classification number: A61K31/505 ,  A61K9/0053 ,  A61K31/4178 ,  A61K31/496 ,  A61K31/513 ,  A61K31/565 ,  A61K31/567

Abstract: The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.

公开(公告)号：US20240299359A1

公开(公告)日：2024-09-12

申请号：US18575394

申请日：2022-06-28

Applicant: KYONGBO PHARM. CO., LTD. ,  NDIC CO., LTD.

Inventor： Jeong Seok HAN, ,  Yong Kyu PARK ,  Sung Hun BANG ,  Jae Hyun KIM ,  Ha Lim JANG ,  Ye Rin KIM ,  Su Kyoung LEE ,  Taek Joo LIM

IPC: A61K31/4166 ,  A61K9/00 ,  A61P13/12

CPC classification number: A61K31/4166 ,  A61K9/0053 ,  A61P13/12

Abstract: Disclosed are a pharmaceutical composition for animals containing 5-hydroxy-1-methylimidazolidine-2,4-dione as an active ingredient, more specifically, a composition for preventing or treating kidney disease in animals containing 5-hydroxy-1-methylimidazolidine-2,4-dione or a pharmaceutically acceptable salt thereof as an active ingredient, a method of treating kidney disease in animals using the compound, and a functional feed for preventing or ameliorating kidney disease in animals containing the compound as an active ingredient. The 5-hydroxy-1-methylimidazolidine-2,4-dione can effectively ameliorate and treat symptoms of kidney disease when administered to companion animals such as dogs or cats with kidney disease. Therefore, there are provided a novel agent and method for treating kidney disease of animals that can effectively treat kidney disease, which is the cause of high mortality in companion animals.

公开(公告)号：US12083119B2

公开(公告)日：2024-09-10

申请号：US17545217

申请日：2021-12-08

Applicant: VIRACTA SUBSIDIARY, INC. ,  TRUSTEES OF BOSTON UNIVERSITY

Inventor： Ronald J. Berenson ,  Douglas V. Faller

IPC: A61K31/506 ,  A61K9/00 ,  A61K31/165 ,  A61K31/167 ,  A61K31/18 ,  A61K31/19 ,  A61K31/27 ,  A61K31/4045 ,  A61K31/4402 ,  A61K31/473 ,  A61K31/513 ,  A61K31/52 ,  A61K31/522 ,  A61K38/12 ,  A61K38/15 ,  A61K45/06

CPC classification number: A61K31/506 ,  A61K9/0053 ,  A61K31/165 ,  A61K31/167 ,  A61K31/18 ,  A61K31/19 ,  A61K31/27 ,  A61K31/4045 ,  A61K31/4402 ,  A61K31/473 ,  A61K31/513 ,  A61K31/52 ,  A61K31/522 ,  A61K38/12 ,  A61K38/15 ,  A61K45/06 ,  Y02A50/30 ,  A61K31/167 ,  A61K2300/00 ,  A61K31/19 ,  A61K2300/00 ,  A61K31/27 ,  A61K2300/00 ,  A61K31/4045 ,  A61K2300/00 ,  A61K31/506 ,  A61K2300/00 ,  A61K31/513 ,  A61K2300/00 ,  A61K38/12 ,  A61K2300/00

Abstract: Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.

公开(公告)号：US12083107B2

公开(公告)日：2024-09-10

申请号：US18049652

申请日：2022-10-26

Applicant: Bjoern Colin Kahrs

Inventor： Bjoern Colin Kahrs

IPC: A61K31/05 ,  A61K9/00 ,  A61K31/12 ,  A61K31/16 ,  A61K31/19 ,  A61K31/216 ,  A61K31/225 ,  A61K31/26 ,  A61K31/385 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/47 ,  A61P1/04 ,  A61P5/48 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/02 ,  A61P21/02 ,  A61P21/04 ,  A61P25/00 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P37/06 ,  A61P43/00

CPC classification number: A61K31/4439 ,  A61K9/0053 ,  A61K31/05 ,  A61K31/12 ,  A61K31/16 ,  A61K31/19 ,  A61K31/216 ,  A61K31/225 ,  A61K31/26 ,  A61K31/385 ,  A61K31/426 ,  A61K31/47 ,  Y02A50/30 ,  A61K31/05 ,  A61K2300/00 ,  A61K31/12 ,  A61K2300/00 ,  A61K31/16 ,  A61K2300/00 ,  A61K31/19 ,  A61K2300/00 ,  A61K31/216 ,  A61K2300/00 ,  A61K31/26 ,  A61K2300/00 ,  A61K31/385 ,  A61K2300/00 ,  A61K31/4439 ,  A61K2300/00 ,  A61K31/47 ,  A61K2300/00

Abstract: The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis.

公开(公告)号：US12083103B2

公开(公告)日：2024-09-10

申请号：US17444402

申请日：2021-08-04

Applicant: Veloxis Pharmaceuticals, Inc.

Inventor： Robert D. Gordon ,  Per Holm ,  Anne-Marie Lademann ,  Tomas Norling

IPC: A61K31/436 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K9/48 ,  A61K47/10

CPC classification number: A61K31/436 ,  A61K9/0053 ,  A61K9/1617 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/284 ,  A61K9/2846 ,  A61K9/4891 ,  A61K47/10

Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.